

Effect of azithromycin on asthma exacerbations and quality of life in patients with persistent uncontrolled asthma (AMAZES): a randomised controlled trial

Lancet, The

390, 659-668

DOI: [10.1016/s0140-6736\(17\)31281-3](https://doi.org/10.1016/s0140-6736(17)31281-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Update in Asthma 2016. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 548-557.	2.5	5
2	Toll-like receptors in COPD. European Respiratory Journal, 2017, 49, 1700739.	3.1	15
3	Personalised medicine: are we ready?. European Respiratory Review, 2017, 26, 170088.	3.0	7
4	Cough and severe asthma. Pulmonary Pharmacology and Therapeutics, 2017, 47, 72-76.	1.1	9
5	Predictive Biomarkers for Asthma Therapy. Current Allergy and Asthma Reports, 2017, 17, 69.	2.4	44
6	Asthma Phenotypes and Endotypes: Implications for Personalised Therapy. BioDrugs, 2017, 31, 393-408.	2.2	20
7	Moving Upstream " Anti-TSLP in Persistent Uncontrolled Asthma. New England Journal of Medicine, 2017, 377, 989-991.	13.9	8
8	Sputum colour can identify patients with neutrophilic inflammation in asthma. BMJ Open Respiratory Research, 2017, 4, e000236.	1.2	13
9	Azithromycin in uncontrolled asthma. Lancet, The, 2017, 390, 629-630.	6.3	5
10	Recognition and management of severe asthma: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 199-221.	0.2	42
11	Azithromycin is a potential option for select patients with asthma. Pharmacy Today, 2017, 23, 33.	0.0	0
13	An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Research, 2018, 4, 00125-2017.	1.1	58
14	Bronchiectasis in severe asthma. Annals of Allergy, Asthma and Immunology, 2018, 120, 409-413.	0.5	51
15	Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis. MSphere, 2018, 3, .	1.3	58
16	Effect of antibiotic use for acute bronchiolitis on new-onset asthma in children. Scientific Reports, 2018, 8, 6090.	1.6	18
17	New biologics for allergic diseases. Expert Review of Clinical Immunology, 2018, 14, 285-296.	1.3	18
18	Neutrophilic Asthma. Archivos De Bronconeumologia, 2018, 54, 187-188.	0.4	0
19	Neutrophilic Asthma. Archivos De Bronconeumologia, 2018, 54, 187-188.	0.4	0

#	ARTICLE	IF	CITATIONS
20	Nuevas opciones terapéuticas en asma. Medicina Clínica, 2018, 151, 16-17.	0.3	0
21	Biomarkers and asthma management: analysis and potential applications. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 96-108.	1.1	21
22	Advancing the management of obstructive airways diseases through translational research. Clinical and Experimental Allergy, 2018, 48, 493-501.	1.4	0
23	Childhood Asthma: Is It All About Bacteria and Not About Viruses? A Pro/Con Debate. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 719-725.	2.0	9
24	Diagnosis and Management of Severe Asthma. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 091-099.	0.8	23
25	Fevipirant in the treatment of asthma. Expert Opinion on Investigational Drugs, 2018, 27, 199-207.	1.9	23
26	Should Antibiotic Prophylaxis Be Routinely Used in Patients with Antibody-Mediated Primary Immunodeficiency?. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 421-426.	2.0	17
27	Asthma. Lancet, The, 2018, 391, 783-800.	6.3	1,105
28	How does azithromycin improve asthma exacerbations? – Author's reply. Lancet, The, 2018, 391, 28-29.	6.3	2
29	How does azithromycin improve asthma exacerbations?. Lancet, The, 2018, 391, 28.	6.3	3
30	New and emerging drug treatments for severe asthma. Clinical and Experimental Allergy, 2018, 48, 241-252.	1.4	32
31	Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. Journal of Allergy and Clinical Immunology, 2018, 141, 2027-2036.e12.	1.5	124
32	Diagnosis and treatment of severe asthma: a phenotype-based approach. Clinical Medicine, 2018, 18, s36-s40.	0.8	45
33	Endotypes in allergic diseases. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 177-183.	1.1	15
34	Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults. European Clinical Respiratory Journal, 2018, 5, 1440868.	0.7	40
35	Azithromycin ameliorates OVA-induced airway remodeling in Balb/c mice via suppression of epithelial-to-mesenchymal transition. International Immunopharmacology, 2018, 58, 87-93.	1.7	35
36	Treatable traits of chronic airways disease. Current Opinion in Pulmonary Medicine, 2018, 24, 24-31.	1.2	24
37	Drug repurposing to treat asthma and allergic disorders: Progress and prospects. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 313-322.	2.7	18

#	ARTICLE	IF	CITATIONS
38	Preview of highlighted presentations from the European Respiratory Society™ clinical assembly. Journal of Thoracic Disease, 2018, 10, S3034-S3042.	0.6	0
40	Protocolo diagnóstico y tratamiento del asma de difícil control. Medicine, 2018, 12, 3726-3728.	0.0	0
41	Health-related quality of life burden in severe asthma. Medical Journal of Australia, 2018, 209, S28-S33.	0.8	62
42	Azithromycin treatment modifies airway and blood gene expression networks in neutrophilic COPD. ERJ Open Research, 2018, 4, 00031-2018.	1.1	17
43	New perspectives of childhood asthma treatment with biologics. Pediatric Allergy and Immunology, 2019, 30, 159-171.	1.1	37
44	Chlamydomydia pneumoniae , A Pathogen Causing More Than Pneumonia. , 2018, , 641-641.		0
45	Biomarkers in asthma: state of the art. Asthma Research and Practice, 2018, 4, 10.	1.2	78
46	Amazing pleiotropic effects of azithromycin. Breathe, 2018, 14, 336-337.	0.6	1
47	Can a temporary increase in corticosteroid dosage reduce asthma exacerbations?. Expert Review of Respiratory Medicine, 2018, 12, 993-995.	1.0	0
48	Antibiotic use in children with asthma: cohort study in UK and Dutch primary care databases. BMJ Open, 2018, 8, e022979.	0.8	19
50	Randomised controlled trials in severe asthma: selection by phenotype or stereotype. European Respiratory Journal, 2018, 52, 1801444.	3.1	70
51	Non-eosinophilic asthma: current perspectives. Journal of Asthma and Allergy, 2018, Volume 11, 267-281.	1.5	81
52	Asthma-COPD overlap: identification and optimal treatment. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661880566.	1.0	35
53	Personalizing the approach to asthma treatment. Expert Review of Precision Medicine and Drug Development, 2018, 3, 299-304.	0.4	3
54	Omalizumab for Severe Asthma: Beyond Allergic Asthma. BioMed Research International, 2018, 2018, 1-10.	0.9	29
55	Challenges in the management of asthma associated with smoking-induced airway diseases. Expert Opinion on Pharmacotherapy, 2018, 19, 1565-1579.	0.9	10
56	Medication Regimens for Managing Stable Asthma. Respiratory Care, 2018, 63, 759-772.	0.8	3
57	Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases. Respiratory Care, 2018, 63, 671-689.	0.8	15

#	ARTICLE	IF	CITATIONS
59	New therapeutic options in asthma. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 16-17.	0.1	0
60	Optimising treatment for severe asthma. <i>Medical Journal of Australia</i> , 2018, 209, S22-S27.	0.8	20
61	Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits. <i>Respiratory Medicine</i> , 2018, 142, 15-22.	1.3	22
62	Azithromycin Clears <i>Bordetella pertussis</i> Infection in Mice but Also Modulates Innate and Adaptive Immune Responses and T Cell Memory. <i>Frontiers in Immunology</i> , 2018, 9, 1764.	2.2	19
63	Life-long antimicrobial therapy: where is the evidence?. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2601-2612.	1.3	20
64	What is New in the Management of Childhood Asthma?. <i>Indian Journal of Pediatrics</i> , 2018, 85, 773-781.	0.3	22
65	Clinical Approach to the Therapy of Asthma-COPD Overlap. <i>Chest</i> , 2019, 155, 168-177.	0.4	44
66	Options of immunotherapeutic treatments for children with asthma. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 937-949.	1.0	6
67	Inhibitory effects of selected antibiotics on the activities of α -amylase and α -glucosidase: In-vitro, in-vivo and theoretical studies. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 138, 105040.	1.9	4
68	Management of asthma COPD overlap. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 335-344.	0.5	25
70	Exacerbations of chronic respiratory diseases. , 2019, , 137-168.		3
71	Asthma in Children and Adults—What Are the Differences and What Can They Tell us About Asthma?. <i>Frontiers in Pediatrics</i> , 2019, 7, 256.	0.9	145
72	Living well with severe asthma. <i>Breathe</i> , 2019, 15, e40-e49.	0.6	21
73	High prevalence of bronchiectasis on chest CT in a selected cohort of children with severe Asthma. <i>BMC Pulmonary Medicine</i> , 2019, 19, 136.	0.8	10
74	Microbiome-focused asthma management strategies. <i>Current Opinion in Pharmacology</i> , 2019, 46, 143-149.	1.7	15
75	Dysregulation of sputum columnar epithelial cells and products in distinct asthma phenotypes. <i>Clinical and Experimental Allergy</i> , 2019, 49, 1418-1428.	1.4	11
76	The Challenges and Opportunities of Maximizing the Benefits of Severe Asthma Registries. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1469-1470.	2.0	1
77	Personalized Medicine and Pediatric Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2019, 39, 221-231.	0.7	3

#	ARTICLE	IF	CITATIONS
78	The "œnvirome" and what the practitioner needs to know about it. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 542-549.	0.5	14
79	Nontuberculous Mycobacteria in Cystic Fibrosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 737-750.	0.8	27
80	Cellular mechanisms underlying steroid-resistant asthma. <i>European Respiratory Review</i> , 2019, 28, 190096.	3.0	63
81	Peering deeper into asthmatic lungs. <i>Respirology</i> , 2019, 24, 1037-1038.	1.3	0
82	ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. <i>European Respiratory Journal</i> , 2019, 54, 1900900.	3.1	56
84	A descriptive follow-up interview study assessing patient-centred outcomes: Salford Lung Study in Asthma (SLS Asthma). <i>Npj Primary Care Respiratory Medicine</i> , 2019, 29, 31.	1.1	1
85	Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. <i>European Respiratory Journal</i> , 2019, 54, 1901381.	3.1	47
86	Lower Airway Microbiota. <i>Frontiers in Pediatrics</i> , 2019, 7, 393.	0.9	38
87	Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 931-940.	1.9	68
88	Nonallergic Triggers and Comorbidities in Asthma Exacerbations and Disease Severity. <i>Clinics in Chest Medicine</i> , 2019, 40, 71-85.	0.8	6
89	The efficacy and safety of azithromycin in asthma: A systematic review. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 1638-1646.	1.6	11
90	Association of Antibiotic Treatment With Outcomes in Patients Hospitalized for an Asthma Exacerbation Treated With Systemic Corticosteroids. <i>JAMA Internal Medicine</i> , 2019, 179, 333.	2.6	29
91	New insights in neutrophilic asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 113-120.	1.2	53
92	Goblet cell hyperplasia as a feature of neutrophilic asthma. <i>Clinical and Experimental Allergy</i> , 2019, 49, 781-788.	1.4	17
93	Nobody Does it Better: A Patient Physician Perspective of Asthma Management. <i>Pulmonary Therapy</i> , 2019, 5, 5-10.	1.1	0
94	Paediatric and adult bronchiectasis: Specific management with coexisting asthma, COPD, rheumatological disease and inflammatory bowel disease. <i>Respirology</i> , 2019, 24, 1063-1072.	1.3	15
95	Azithromycin induces epidermal differentiation and multivesicular bodies in airway epithelia. <i>Respiratory Research</i> , 2019, 20, 129.	1.4	17
96	Placebo Effects in Clinical Trials Evaluating Patients with Uncontrolled Persistent Asthma. <i>Annals of the American Thoracic Society</i> , 2019, 16, 1124-1130.	1.5	20

#	ARTICLE	IF	CITATIONS
97	Functional effects of the microbiota in chronic respiratory disease. <i>Lancet Respiratory Medicine</i> , 2019, 7, 907-920.	5.2	269
98	Not just the common cold: Rhinovirus infection in lung allograft recipients. <i>Respirology</i> , 2019, 24, 1134-1135.	1.3	0
99	<p>Pneumonia in young adults with asthma: impact on subsequent asthma exacerbations</p>. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 95-99.	1.5	8
100	Dismantling the pathophysiology of asthma using imaging. <i>European Respiratory Review</i> , 2019, 28, 180111.	3.0	20
101	Azithromycin: The Holy Grail to Prevent Exacerbations in Chronic Respiratory Disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 269-270.	2.5	11
102	Two Sides of the Same Coin?â€”Treatment of Chronic Asthma in Children and Adults. <i>Frontiers in Pediatrics</i> , 2019, 7, 62.	0.9	11
104	Long-Term Azithromycin Reduces <i>Haemophilus influenzae</i> and Increases Antibiotic Resistance in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 309-317.	2.5	121
105	Toward clinically applicable biomarkers for asthma: An <scp>EAACI</scp> position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1835-1851.	2.7	135
106	Exhaled Volatile Organic Compounds Are Able to Discriminate between Neutrophilic and Eosinophilic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 444-453.	2.5	115
107	Referral Criteria for Asthma: Consensus Document. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 422-430.	0.6	17
108	Asthma: An Undermined State of Immunodeficiency. <i>International Reviews of Immunology</i> , 2019, 38, 70-78.	1.5	14
109	<p>Future perspectives of anticholinergics for the treatment of asthma in adults and children</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 473-485.	0.9	12
110	Idiopathic chronic productive cough and response to openâ€”label macrolide therapy: An observational study. <i>Respirology</i> , 2019, 24, 558-565.	1.3	16
111	Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 823-829.	2.5	31
112	The health effects of Baduanjin exercise (a type of Qigong exercise) in breast cancer survivors: A randomized, controlled, single-blinded trial. <i>European Journal of Oncology Nursing</i> , 2019, 39, 90-97.	0.9	34
113	A sputum 6-gene signature predicts future exacerbations of poorly controlled asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 51-60.e11.	1.5	50
114	Do recent research studies validate the medicinal plants used in British Columbia, Canada for pet diseases and wild animals taken into temporary care?. <i>Journal of Ethnopharmacology</i> , 2019, 236, 366-392.	2.0	19
115	Beyond steroids and bronchodilators â€” investigating additional therapies for horses with severe equine asthma. <i>Veterinary Record</i> , 2019, 185, 140-142.	0.2	1

#	ARTICLE	IF	CITATIONS
116	Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. ERJ Open Research, 2019, 5, 00056-2019.	1.1	27
117	Randomised study of the immunomodulatory effects of azithromycin in severely asthmatic horses. Veterinary Record, 2019, 185, 143-143.	0.2	8
118	Adverse events in people taking macrolide antibiotics versus placebo for any indication. The Cochrane Library, 2019, 2019, CD011825.	1.5	55
119	Immunological biomarkers in severe asthma. Seminars in Immunology, 2019, 46, 101332.	2.7	35
120	Linezolid and Its Immunomodulatory Effect: In Vitro and In Vivo Evidence. Frontiers in Pharmacology, 2019, 10, 1389.	1.6	9
121	Lung Microbiome in Asthma: Current Perspectives. Journal of Clinical Medicine, 2019, 8, 1967.	1.0	51
122	Severe asthma in children: therapeutic considerations. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 132-140.	1.1	8
123	The efficacy and safety of long-term add-on treatment of azithromycin in asthma. Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlo	0.4	10
124	Bacteria in Asthma Pathogenesis. Immunology and Allergy Clinics of North America, 2019, 39, 377-389.	0.7	2
125	Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respiriology, 2019, 24, 37-47.	1.3	136
126	Transcriptional and functional diversity of human macrophage repolarization. Journal of Allergy and Clinical Immunology, 2019, 143, 1536-1548.	1.5	49
127	Mechanisms and Management of Asthma Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 423-432.	2.5	83
129	The microbiome in asthma. Annals of Allergy, Asthma and Immunology, 2019, 122, 270-275.	0.5	65
130	Diffuse panbronchiolitis: A progressive fatal lung disease that is curable with azithromycin, but only if diagnosed!. Pediatric Pulmonology, 2019, 54, 457-462.	1.0	8
131	Clarithromycin suppresses IL-13-induced goblet cell metaplasia via the TMEM16A-dependent pathway in guinea pig airway epithelial cells. Respiratory Investigation, 2019, 57, 79-88.	0.9	7
132	Bronchiectasis and asthma: a dangerous liaison?. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 46-52.	1.1	34
133	Azithromycin inhibits muscarinic 2 receptor-activated and voltage-activated Ca ²⁺ permeant ion channels and Ca ²⁺ sensitization, relaxing airway smooth muscle contraction. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 329-336.	0.9	9
134	What's new in the Global Initiative for Asthma 2018 report and beyond. Allergo Journal International, 2019, 28, 63-72.	0.9	14

#	ARTICLE	IF	CITATIONS
135	Role of Biologics in Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 433-445.	2.5	296
136	New-Onset Asthma in Adults: What Does the Trigger History Tell Us?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 898-905.e1.	2.0	11
137	The contribution of respiratory microbiome analysis to a treatable traits model of care. Respiriology, 2019, 24, 19-28.	1.3	8
138	Endotype-Driven Approach for Asthma. , 2019, , 45-49.		2
139	Azithromycin treatment in children hospitalized with asthma: a retrospective cohort study. Journal of Asthma, 2020, 57, 525-531.	0.9	5
140	Meeting the Challenge of Identifying New Treatments for Type 2-Low Neutrophilic Asthma. Chest, 2020, 157, 26-33.	0.4	35
141	Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 2020, 55, 1900588.	3.1	380
142	Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a <i>Haemophilus</i> -predominant subgroup. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 808-817.	2.7	33
143	Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes. Paediatric Respiratory Reviews, 2020, 36, 118-127.	1.2	56
144	Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 302-310.	2.7	68
145	Mechanisms and therapeutic strategies for non- $\text{C}2$ asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 311-325.	2.7	148
147	Rational oral corticosteroid use in adult severe asthma: A narrative review. Respiriology, 2020, 25, 161-172.	1.3	58
148	Recent Advances in Severe Asthma. Chest, 2020, 157, 516-528.	0.4	96
149	Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 430-437.	2.5	50
151	Asthma-COPD Overlap and Chronic Airflow Obstruction: Definitions, Management, and Unanswered Questions. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 483-495.	2.0	24
152	Are macrolides beneficial in treating childhood asthma?. Archives of Disease in Childhood, 2020, 105, 306-309.	1.0	2
153	Exploring the clinical relevance of cough hypersensitivity syndrome. Expert Review of Respiratory Medicine, 2020, 14, 275-284.	1.0	12
154	Steroid-Resistant Asthma and Neutrophils. Biological and Pharmaceutical Bulletin, 2020, 43, 31-35.	0.6	73

#	ARTICLE	IF	CITATIONS
155	Contemporary management techniques of asthma in obese patients. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 249-257.	1.0	2
156	The non-antibiotic macrolide EM900 attenuates HDM and poly(I:C)-induced airway inflammation with inhibition of macrophages in a mouse model. <i>Inflammation Research</i> , 2020, 69, 139-151.	1.6	21
157	Influence of azithromycin and allograft rejection on the post-lung transplant microbiota. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 176-183.	0.3	22
158	Targeting treatable traits in severe asthma: a randomised controlled trial. <i>European Respiratory Journal</i> , 2020, 55, 1901509.	3.1	121
159	Efficacy of immunoglobulin replacement therapy and azithromycin in severe asthma with antibody deficiency. <i>Allergology International</i> , 2020, 69, 215-222.	1.4	8
160	Exacerbation-Prone Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 474-482.	2.0	37
161	Targeting neutrophils in asthma: A therapeutic opportunity?. <i>Biochemical Pharmacology</i> , 2020, 182, 114292.	2.0	18
162	Attenuating COVID-19 infection and inflammation: Lessons from asthma. <i>Respirology</i> , 2020, 25, 1233-1234.	1.3	2
163	Mitochondrial dysfunction in lung ageing and disease. <i>European Respiratory Review</i> , 2020, 29, 200165.	3.0	56
164	Japanese guidelines for adult asthma 2020. <i>Allergology International</i> , 2020, 69, 519-548.	1.4	94
165	Interventional low-dose azithromycin attenuates cigarette smoke-induced emphysema and lung inflammation in mice. <i>Physiological Reports</i> , 2020, 8, e14419.	0.7	8
166	The efficacy and safety of azithromycin in chronic respiratory diseases related cough. <i>Annals of Palliative Medicine</i> , 2020, 9, 1488-1496.	0.5	3
167	Pharmacological ablation of the airway smooth muscle layer—Mathematical predictions of functional improvement in asthma. <i>Physiological Reports</i> , 2020, 8, e14451.	0.7	13
168	Management of severe asthma: summary of the European Respiratory Society/American Thoracic Society task force report. <i>Breathe</i> , 2020, 16, 200058.	0.6	5
169	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2397.	1.0	6
170	Identification of asthma phenotypes based on extrapulmonary treatable traits. <i>European Respiratory Journal</i> , 2021, 57, 2000240.	3.1	27
171	Pharmacotherapeutic management of asthma in the elderly patient. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1991-2010.	0.9	4
172	Asthma: Pharmacological degradation of the airway smooth muscle layer. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 126, 105818.	1.2	12

#	ARTICLE	IF	CITATIONS
173	Modern View of Neutrophilic Asthma Molecular Mechanisms and Therapy. <i>Biochemistry (Moscow)</i> , 2020, 85, 854-868.	0.7	18
174	Azithromycin Differentially Alters TCR-Activated Helper T Cell Subset Phenotype and Effector Function. <i>Frontiers in Immunology</i> , 2020, 11, 556579.	2.2	7
175	Exploration of plasma interleukin-27 levels in asthma patients and the correlation with lung function. <i>Respiratory Medicine</i> , 2020, 175, 106208.	1.3	5
176	A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. <i>Trials</i> , 2020, 21, 718.	0.7	25
177	Towards a personalised treatment approach for asthma attacks. <i>Thorax</i> , 2020, 75, 1119-1129.	2.7	13
178	Azithromycin for severe COVID-19. <i>Lancet, The</i> , 2020, 396, 936-937.	6.3	59
179	<p>A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 2091-2100.	0.9	27
180	Resident Memory T Cells. , 2020, , .		1
181	Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach. <i>Journal of Clinical Medicine</i> , 2020, 9, 2623.	1.0	8
182	Traitements de palier 5 dans lâ€™asthme. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, S11-S14.	0.0	0
183	Asthma and COVIDâ€™19: Is asthma a risk factor for severe outcomes?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1543-1545.	2.7	95
184	Update in Asthma 2019. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 184-192.	2.5	5
185	Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic. <i>Respirology</i> , 2020, 25, 1243-1249.	1.3	17
186	Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1008-1015.	1.5	27
187	Documento de consenso de asma grave en adultos. ActualizaciÃ³n 2020. <i>Open Respiratory Archives</i> , 2020, 2, 158-174.	0.0	24
188	Airway abundance of <i>Haemophilus influenzae</i> predicts response to azithromycin in adults with persistent uncontrolled asthma. <i>European Respiratory Journal</i> , 2020, 56, 2000194.	3.1	31
189	Host Directed Therapy Against Infection by Boosting Innate Immunity. <i>Frontiers in Immunology</i> , 2020, 11, 1209.	2.2	37
190	The Link between Asthma and Bronchiectasis: State of the Art. <i>Respiration</i> , 2020, 99, 463-476.	1.2	32

#	ARTICLE	IF	CITATIONS
191	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2503-2541.	2.7	95
192	Emerging therapeutic targets and preclinical models for severe asthma. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 845-857.	1.5	5
193	Bronchial thermoplasty: Redefining its role. <i>Respirology</i> , 2020, 25, 981-986.	1.3	7
194	Metagenomic Characterization of the Respiratory Microbiome. A Piece de Résistance. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 321-322.	2.5	5
195	Management of Severe Asthma Beyond the Guidelines. <i>Current Allergy and Asthma Reports</i> , 2020, 20, 47.	2.4	4
196	The evolving algorithm of biological selection in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1555-1563.	2.7	30
197	Beyond type 2 cytokines in asthma - new insights from old clinical trials. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 463-475.	1.5	9
198	Is bronchiectasis really a disease?. <i>European Respiratory Review</i> , 2020, 29, 190051.	3.0	10
199	The management of severe asthma in 2020. <i>Biochemical Pharmacology</i> , 2020, 179, 114112.	2.0	46
200	The Nonantibiotic Macrolide EM900 Attenuates House Dust Mite-Induced Airway Inflammation in a Mouse Model of Obesity-Associated Asthma. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 665-674.	0.9	8
201	Natural history of COVID-19 and current knowledge on treatment therapeutic options. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110493.	2.5	118
202	How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?. <i>Clinical and Experimental Allergy</i> , 2020, 50, 994-1006.	1.4	11
203	Altered gut microbiota by azithromycin attenuates airway inflammation in allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1466-1469.e8.	1.5	20
204	Potential Role of Cellular Senescence in Asthma. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 59.	1.8	24
205	Severe asthma: what is new in the new millennium. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 202-207.	1.1	8
206	Eosinophilic vs. Neutrophilic Asthma. <i>Current Pulmonology Reports</i> , 2020, 9, 28-35.	0.5	5
207	New Therapeutic Strategies for Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 517.	3.8	5
208	Management of Acute Asthma in Adults in 2020. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 563.	3.8	11

#	ARTICLE	IF	CITATIONS
209	Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. <i>Lancet</i> , The, 2020, 395, 371-383.	6.3	102
210	Similarities and differences in the effects of sensitisation and challenge with <i>Dermatophagoides farinae</i> and <i>Dermatophagoides pteronyssinus</i> extracts in a murine asthma surrogate. <i>Cellular Immunology</i> , 2020, 348, 104038.	1.4	3
211	The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS). <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 213-231.	0.9	27
212	T2-â€œLowâ€•Asthma: Overview and Management Strategies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 452-463.	2.0	82
213	Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 78.	1.1	21
214	Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVIDâ€™19. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 201-211.	2.3	129
215	British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. <i>Thorax</i> , 2020, 75, 370-404.	2.7	31
216	BTS guideline on long-term macrolides in adults with respiratory disease: not quite a panacea. <i>Thorax</i> , 2020, 75, 405-406.	2.7	2
217	EAACI Biologicals Guidelinesâ€™Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 14-44.	2.7	156
218	Association between early antibiotic treatment and clinical outcomes in children hospitalized for asthma exacerbation. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 114-122.e14.	1.5	9
219	Treatment options in type-2 low asthma. <i>European Respiratory Journal</i> , 2021, 57, 2000528.	3.1	80
220	Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators. <i>Inflammopharmacology</i> , 2021, 29, 15-33.	1.9	8
221	Impact of diet and the bacterial microbiome on the mucous barrier and immune disorders. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 714-734.	2.7	66
222	Eosinophils and the burden of airway disease. <i>Respirology</i> , 2021, 26, 6-7.	1.3	1
223	Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications?. , 2021, 219, 107703.		50
224	The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma. <i>European Respiratory Journal</i> , 2021, 57, 2002436.	3.1	4
225	What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance. <i>ERJ Open Research</i> , 2021, 7, 00497-2020.	1.1	28
226	Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial. <i>Annals of the American Thoracic Society</i> , 2021, 18, 590-597.	1.5	28

#	ARTICLE	IF	CITATIONS
227	Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 809-821.	2.5	72
228	The Gut Microbiome and Ozone-induced Airway Hyperresponsiveness. Mechanisms and Therapeutic Prospects. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 283-291.	1.4	14
229	Azithromycin in viral infections. Reviews in Medical Virology, 2021, 31, e2163.	3.9	89
230	Association between selected urinary heavy metals and asthma in adults: a retrospective cross-sectional study of the US National Health and Nutrition Examination Survey. Environmental Science and Pollution Research, 2021, 28, 5833-5844.	2.7	4
231	Composite type-2 biomarker strategy versus a symptomâ€‘risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 57-68.	5.2	88
232	Pharmacological Management of Cough. , 2021, , 55-63.		0
233	Inflammatory Mechanism and Clinical Implication of Asthma in COVID-19. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2021, 15, 117954842110427.	0.5	6
234	The Role of Upper Airway Microbiome in the Development of Adult Asthma. Immune Network, 2021, 21, e19.	1.6	19
235	Novel Immunomodulatory Therapies for Respiratory Pathologies. , 2022, , 554-594.		5
236	Applying personalized medicine to adult severe asthma. Allergy and Asthma Proceedings, 2021, 42, e8-e16.	1.0	4
237	Add-on azithromycin reduces sputum cytokines in non-eosinophilic asthma: an AMAZES substudy. Thorax, 2021, 76, 733-736.	2.7	16
238	The role of neutrophils in asthma. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2021, 50, 123-130.	0.1	3
239	Neutrophils in asthma: the good, the bad and the bacteria. Thorax, 2021, 76, 835-844.	2.7	58
240	Chronic infection with Chlamydia pneumoniae in asthma: a type-2 low infection related phenotype. Respiratory Research, 2021, 22, 72.	1.4	9
241	Patterns of azithromycin use in obstructive airway diseases: a realâ€‘world observational study. Internal Medicine Journal, 2022, 52, 1016-1023.	0.5	3
242	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. Frontiers in Immunology, 2021, 12, 574425.	2.2	38
243	Balancing the needs of the many and the few: where next for adult asthma guidelines?. Lancet Respiratory Medicine,the, 2021, 9, 786-794.	5.2	18
244	An Overview of Drugs Used in COVID-19: A Pharmacotherapeutic Approach. International Journal of Health Sciences and Pharmacy, 0, , 34-54.	0.0	0

#	ARTICLE	IF	CITATIONS
245	BTS guideline for the use of long-term macrolides. Drug and Therapeutics Bulletin, 2021, 59, 67-68.	0.3	0
246	Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2090-2101.	2.7	27
247	The Patientsâ€™ Experience of Severe Asthma Add-On Pharmacotherapies: A Qualitative Descriptive Study. Journal of Asthma and Allergy, 2021, Volume 14, 245-258.	1.5	14
248	Target Product Profile and Development Path for Shigellosis Treatment with Antibacterials. ACS Infectious Diseases, 2021, 7, 948-958.	1.8	3
249	The Gut/Lung Microbiome Axis in Obesity, Asthma, and Bariatric Surgery: A Literature Review. Obesity, 2021, 29, 636-644.	1.5	29
250	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. European Respiratory Journal, 2021, 57, 2100048.	3.1	152
251	Phenotype-Guided Asthma Therapy: An Alternative Approach to Guidelines. Journal of Asthma and Allergy, 2021, Volume 14, 207-217.	1.5	7
252	Azithromycin in the Successful Management of COVID-19: A Family Physicianâ€™s Perspective. Cureus, 2021, 13, e14574.	0.2	0
253	Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19. Frontiers in Medicine, 2021, 8, 642313.	1.2	10
254	Current and New Drugs for COVID-19 Treatment and Its Effects on the Liver. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	0.7	6
255	Treatable Traits in Elderly Asthmatics from the Australasian Severe Asthma Network: A Prospective Cohort Study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2770-2782.	2.0	15
256	Azithromycin Use in COVID-19 Patients: Implications on the Antimicrobial Resistance. Current Topics in Medicinal Chemistry, 2021, 21, 677-683.	1.0	4
257	Bronchial thermoplasty: 10 years and counting. Lancet Respiratory Medicine, the, 2021, 9, 436-437.	5.2	0
258	Implications of preexisting asthma on COVID-19 pathogenesis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L880-L891.	1.3	22
259	Role of Innate Immune System in Environmental Lung Diseases. Current Allergy and Asthma Reports, 2021, 21, 34.	2.4	9
260	Antimicrobial Peptides SLPI and Beta Defensin-1 in Sputum are Negatively Correlated with FEV1. International Journal of COPD, 2021, Volume 16, 1437-1447.	0.9	6
261	Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction. Journal of Asthma and Allergy, 2021, Volume 14, 525-538.	1.5	6
262	Cyclophilin A Plays Potential Roles in a Rat Model of Asthma and Suppression of Immune Response. Journal of Asthma and Allergy, 2021, Volume 14, 471-480.	1.5	1

#	ARTICLE	IF	CITATIONS
263	Management of adult asthma and chronic rhinitis as one airway disease. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1135-1147.	1.0	4
264	Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. <i>Pulmonologia</i> , 2021, 31, 272-295.	0.2	0
265	Update on Asthmaâ€œCOPD Overlap (ACO): A Narrative Review. <i>International Journal of COPD</i> , 2021, Volume 16, 1783-1799.	0.9	46
266	Highlights in the advances of chronic rhinosinusitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3349-3358.	2.7	27
267	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. <i>European Respiratory Journal</i> , 2022, 59, 2100752.	3.1	31
268	Outcomes of Antibiotics in Adults with â€œDifficult to Treatâ€Asthma or the Overlap Syndrome. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 703-712.	1.5	3
269	Management Strategies to Reduce Exacerbations in non-T2 Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2588-2597.	2.0	10
270	Prevention and Treatment of Asthma Exacerbations in Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2578-2586.	2.0	13
271	Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 645-659.	1.5	17
272	Biomarkers of asthma. <i>Minerva Medica</i> , 2022, 113, .	0.3	9
273	Azithromycin induces apoptosis in airway smooth muscle cells through mitochondrial pathway in a rat asthma model. <i>Annals of Translational Medicine</i> , 2021, 9, 1181-1181.	0.7	2
274	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3997-4004.	2.0	74
275	Dangerous liaisons: Bacteria, antimicrobial therapies, and allergic diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3276-3291.	2.7	9
276	Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection. <i>European Journal of Pharmacology</i> , 2021, 905, 174191.	1.7	27
277	Sars-Cov-2 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National Cross-Sectional Study. <i>Antibiotics</i> , 2021, 10, 1039.	1.5	1
278	Treatment approaches for the patient with T2 low asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 530-535.	0.5	8
279	Development of an operational definition of treatment escalation in adults with asthma adapted to healthcare administrative databases: A Delphi study. <i>Respiratory Medicine</i> , 2021, 185, 106510.	1.3	3
280	Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 873-884.	5.2	99

#	ARTICLE	IF	CITATIONS
281	Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial. <i>Respiratory Medicine</i> , 2021, 185, 106494.	1.3	10
282	Asthma and Comorbid Conditionsâ€™ Pulmonary Comorbidity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3868-3875.	2.0	13
283	Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease. <i>Breathe</i> , 2021, 17, 210053.	0.6	8
284	Asthma COPD overlap: Insights into cellular and molecular mechanisms. <i>Molecular Aspects of Medicine</i> , 2022, 85, 101021.	2.7	12
285	Transcriptomic drug-response gene signatures are informative for the stratification of patients for clinical trials. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 55-57.	1.5	0
286	Cost-utility of azithromycin in patients with severe asthma. <i>Journal of Asthma</i> , 2022, 59, 2008-2015.	0.9	6
287	Recent Insights into the Management of Inflammation in Asthma. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4371-4397.	1.6	18
288	Azithromycin modulates Teff/Treg balance in retinal inflammation via the mTOR signaling pathway. <i>Biochemical Pharmacology</i> , 2021, 193, 114793.	2.0	3
289	Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand. <i>Respirology</i> , 2021, 26, 1112-1130.	1.3	35
290	Treatment Response Biomarkers in Asthma and COPD. <i>Diagnostics</i> , 2021, 11, 1668.	1.3	5
292	The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1174-1184.	5.2	49
293	Microbiome Therapeutics in Respiratory Illnesses. , 2022, , 331-341.		0
294	Biological Therapies for Asthma. , 2022, , 411-434.		3
295	Adult Severe Asthma. , 2022, , 383-399.		0
296	Acute Asthma. , 2022, , 278-295.		0
297	Asthmaâ€™ COPD Overlap. , 2022, , 702-711.		0
298	Expert recommendations on the role of macrolides in chronic respiratory diseases. <i>Lung India</i> , 2021, 38, 174.	0.3	0
299	Immunomodulatory Effect of Colistin and its Protective Role in Rats with Methicillin-Resistant <i>Staphylococcus aureus</i> -induced Pneumonia. <i>Frontiers in Pharmacology</i> , 2020, 11, 602054.	1.6	3

#	ARTICLE	IF	CITATIONS
300	Asthmatic patients. , 2021, , 136-153.		0
301	Antiviral Activity of Azithromycin (A Synthetic Macrolide) for Next Step of COVID-19. Asian Journal of Chemistry, 2021, 33, 1594-1602.	0.1	0
302	A real-life comparative effectiveness study into the addition of antibiotics to the management of asthma exacerbations in primary care. European Respiratory Journal, 2021, 58, 2003599.	3.1	11
303	The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children. Annals of Thoracic Medicine, 2021, 16, 4.	0.7	34
304	Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2070-2078.	2.7	18
305	Childhood asthma heterogeneity at the era of precision medicine: Modulating the immune response or the microbiota for the management of asthma attack. Biochemical Pharmacology, 2020, 179, 114046.	2.0	16
306	Why do some asthma patients respond poorly to glucocorticoid therapy?. Pharmacological Research, 2020, 160, 105189.	3.1	53
307	Phenotypes and endotypes. , 0, , 133-152.		1
308	Cardiovascular side-effects of common antibiotics. , 2020, , 264-278.		1
309	Biological treatments for severe asthma. Yeungnam University Journal of Medicine, 2020, 37, 262-268.	0.7	9
310	2020 Brazilian Thoracic Association recommendations for the management of asthma. Jornal Brasileiro De Pneumologia, 2020, 46, e20190307.	0.4	27
311	Managing the overlap of asthma and chronic obstructive pulmonary disease. Australian Prescriber, 2020, 43, 7-11.	0.5	7
312	Novel Biological Therapies in Severe Asthma: Targeting the Right Trait. Current Medicinal Chemistry, 2019, 26, 2801-2822.	1.2	6
313	Role of Lung Microbiome in Innate Immune Response Associated With Chronic Lung Diseases. Frontiers in Medicine, 2020, 7, 554.	1.2	43
314	Azithromycin in Coronavirus Disease-19: What We Know?. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 92-96.	0.1	2
315	The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children. Annals of Thoracic Medicine, 2019, 14, 3.	0.7	45
316	Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma. Allergy, Asthma and Immunology Research, 2020, 12, 910.	1.1	19
317	Effectiveness of benralizumab in severe eosinophilic asthma: Distinct subâ€phenotypes of response identified by cluster analysis. Clinical and Experimental Allergy, 2022, 52, 312-323.	1.4	19

#	ARTICLE	IF	CITATIONS
318	Asthma-COPD Overlap. Chest, 2022, 161, 330-344.	0.4	22
319	A Role for Mucolytics and Expectorants in Aiding Inhaled Therapies in Asthma? [Response To Letter]. Journal of Inflammation Research, 2021, Volume 14, 5183-5185.	1.6	2
321	Precision Medicine for Allergic Airway Diseases. Practica Otologica, 2018, 111, 151-156.	0.0	0
322	Future Treatment and Other New Biologics for Asthma. Respiratory Disease Series, 2019, , 177-189.	0.1	0
324	Clinical phenotypes of severe asthma: adults. , 2019, , 48-63.		1
325	Corticosteroid responsiveness and resistance in severe asthma. , 2019, , 211-230.		1
326	Severe asthma management in adults. , 2019, , 315-326.		0
327	Practical Considerations in Management of Non-eosinophilic Asthma. Respiratory Medicine, 2020, , 207-227.	0.1	0
328	Practical Considerations in the Management of Eosinophilic Asthma. Respiratory Medicine, 2020, , 181-206.	0.1	0
330	Potential Therapeutic Options for Severe Asthma in Children: Lessons from Adult Trials. , 2020, , 287-312.		0
331	Place of azithromycin in the treatment of community-acquired pneumonia in children. Aktualnã Infektologiã, 2020, 8, 38-44.	0.1	0
332	Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacological Reviews, 2021, 73, 1404-1433.	7.1	40
333	Taste Receptors: The Gatekeepers of the Airway Epithelium. Cells, 2021, 10, 2889.	1.8	7
334	Testing the effects of combining azithromycin with inhaled tobramycin for <i>P. aeruginosa</i> in cystic fibrosis: a randomised, controlled clinical trial. Thorax, 2022, 77, 581-588.	2.7	12
335	Azithromycin as an add-on treatment for persistent uncontrolled asthma in adults: protocol of a systematic review and meta-analysis. BMJ Open, 2020, 10, e032770.	0.8	0
336	Management of Status Asthmaticus. , 2020, , 175-182.		0
337	Recent Practice Patterns and Variations in Children Hospitalized for Asthma Exacerbation in Japan. International Archives of Allergy and Immunology, 2020, 181, 926-933.	0.9	4
338	Bronchial Asthma: Current Trends in Treatment. Acta Medica Martiniana, 2020, 20, 9-17.	0.4	2

#	ARTICLE	IF	CITATIONS
339	The immunomodulatory effects of macrolide antibiotics in respiratory disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 71, 102095.	1.1	41
340	Clinical features and mechanistic insights into drug repurposing for combating COVID-19. <i>International Journal of Biochemistry and Cell Biology</i> , 2022, 142, 106114.	1.2	12
341	Flexible Bronchoscopy and Pediatric Asthma. <i>Respiratory Medicine</i> , 2021, , 295-316.	0.1	0
342	Identification and treatment of T2-low asthma in the era of biologics. <i>ERJ Open Research</i> , 2021, 7, 00309-2020.	1.1	44
344	Early administration of Ivermectin, Azithromycin & Doxycycline along with I.V. Prednisolone in a case of COVID -19 disease may lead to early recovery?. <i>International Journal of Pharmaceutical Chemistry and Analysis</i> , 2020, 7, 149-150.	0.1	3
346	Effects of azithromycin on treating chronic obstructive pulmonary disease with acute exacerbation of chronic bronchitis in the stable phase. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 7370-7375.	0.0	0
348	Viral Induced Effects on a Vulnerable Epithelium; Lessons Learned From Paediatric Asthma and Eosinophilic Oesophagitis. <i>Frontiers in Immunology</i> , 2021, 12, 773600.	2.2	5
349	Macrolides versus placebo for chronic asthma. <i>The Cochrane Library</i> , 2021, 2021, CD002997.	1.5	4
350	Distribution of inflammatory phenotypes among patients with asthma in Jilin Province, China: a cross-sectional study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 364.	0.8	5
351	The efficacy and safety of azithromycin in treatment for childhood asthma: A systematic review and meta-analysis. <i>Pediatric Pulmonology</i> , 2022, 57, 631-639.	1.0	6
352	Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society – 2021 update. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2021, 24, .	0.3	5
353	The Role of the Microbiome in Asthma Inception and Phenotype. <i>Respiratory Medicine</i> , 2022, , 85-146.	0.1	1
354	The onset, development and pathogenesis of severe neutrophilic asthma. <i>Immunology and Cell Biology</i> , 2022, 100, 144-159.	1.0	15
355	Effects of azithromycin on bronchial remodeling in the natural model of severe neutrophilic asthma in horses. <i>Scientific Reports</i> , 2022, 12, 446.	1.6	1
356	TH17 cells and corticosteroid insensitivity in severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 467-479.	1.5	31
357	Carriage and Transmission of Macrolide Resistance Genes in Patients With Chronic Respiratory Conditions and Their Close Contacts. <i>Chest</i> , 2022, 162, 56-65.	0.4	0
359	Should we apply a treatable traits approach to asthma care?. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 390-397.	0.5	10
360	Difficult-to-Control Asthma Management in Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 378-384.	2.0	7

#	ARTICLE	IF	CITATIONS
361	Asthma with Fixed Airflow Obstruction: From Fixed to Personalized Approach. <i>Journal of Personalized Medicine</i> , 2022, 12, 333.	1.1	9
362	Azithromycin for Poorly Controlled Asthma in Children. <i>Chest</i> , 2022, 161, 1456-1464.	0.4	16
363	Asthma remission: what is it and how can it be achieved?. <i>European Respiratory Journal</i> , 2022, 60, 2102583.	3.1	61
364	Identifying Bacterial Airways Infection in Stable Severe Asthma Using Oxford Nanopore Sequencing Technologies. <i>Microbiology Spectrum</i> , 2022, 10, e0227921.	1.2	5
365	Azithromycin inhibits mucin secretion, mucous metaplasia, airway inflammation, and airways hyperresponsiveness in mice exposed to house dust mite extract. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 322, L683-L698.	1.3	5
366	Assessment of Long-Term Macrolide Exposure on the Oropharyngeal Microbiome and Macrolide Resistance in Healthy Adults and Consequences for Onward Transmission of Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0224621.	1.4	6
367	Delivering macrolide antibiotics to heal a broken heart – And other inflammatory conditions. <i>Advanced Drug Delivery Reviews</i> , 2022, 184, 114252.	6.6	5
368	Which Therapy for Non-Type(T)2/T2-Low Asthma. <i>Journal of Personalized Medicine</i> , 2022, 12, 10.	1.1	15
369	Acute respiratory syndrome-2 (SARS-CoV-2): A solution of hydrogen peroxide and sodium bicarbonate as an expectorant for recanalization of the respiratory tract and blood oxygenation in respiratory obstruction (review). <i>Reviews on Clinical Pharmacology and Drug Therapy</i> , 2021, 19, 383-393.	0.2	2
370	2021 Brazilian Thoracic Association recommendations for the management of severe asthma. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, e20210273.	0.4	9
371	Severe asthma in children. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 329-340.	0.5	1
378	Mechanism of action, resistance, synergism, and clinical implications of azithromycin. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24427.	0.9	18
380	Impact of Therapeutics on Unified Immunity During Allergic Asthma and Respiratory Infections. <i>Frontiers in Allergy</i> , 2022, 3, 852067.	1.2	3
381	Research Progress on Drugs for the Treatment of Bronchial Asthma. <i>Advances in Clinical Medicine</i> , 2022, 12, 3512-3519.	0.0	0
382	Asthma-COPD Overlap Syndrome: Recent Insights and Unanswered Questions. <i>Journal of Personalized Medicine</i> , 2022, 12, 708.	1.1	15
383	Chronic cough in asthma is associated with increased airway inflammation, more comorbidities, and worse clinical outcomes. <i>Allergy and Asthma Proceedings</i> , 2022, 43, 209-219.	1.0	6
384	Neutrophils and Asthma. <i>Diagnostics</i> , 2022, 12, 1175.	1.3	17
385	Cigarette Smoking and Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2783-2797.	2.0	24

#	ARTICLE	IF	CITATIONS
386	Paucigranulocytic Asthma: Potential Pathogenetic Mechanisms, Clinical Features and Therapeutic Management. <i>Journal of Personalized Medicine</i> , 2022, 12, 850.	1.1	8
387	Azithromycin-Induced Liver Injury in an Asthma Exacerbation Patient With Autoimmune Features. <i>Cureus</i> , 2022, , .	0.2	0
388	Characteristics, phenotypes, mechanisms and management of severe asthma. <i>Chinese Medical Journal</i> , 2022, 135, 1141-1155.	0.9	12
389	Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome. <i>European Respiratory Review</i> , 2022, 31, 210259.	3.0	10
390	An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1205-1216.	0.9	4
391	Research Progress on the Application of Biological Agents in Children with Refractory Asthma. <i>Advances in Clinical Medicine</i> , 2022, 12, 5286-5293.	0.0	0
393	Reduced bronchodilator reversibility correlates with non-type 2 high asthma and future exacerbations: A prospective cohort study. <i>Respiratory Medicine</i> , 2022, 200, 106924.	1.3	3
394	Body Composition-Specific Asthma Phenotypes: Clinical Implications. <i>Nutrients</i> , 2022, 14, 2525.	1.7	0
395	Novel Therapeutic Strategies in Asthma-Chronic Obstructive Pulmonary Disease Overlap. <i>Immunology and Allergy Clinics of North America</i> , 2022, , .	0.7	0
396	Investigational approaches for unmet need in severe asthma. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 661-678.	1.0	2
398	Long-Term, Low-Dose Azithromycin for Uncontrolled Asthma in Children. <i>Chest</i> , 2022, 162, 27-29.	0.4	3
399	Asthma and Tobacco Smoking. <i>Journal of Personalized Medicine</i> , 2022, 12, 1231.	1.1	5
400	We need to understand why viral infections lead to acute asthma. <i>European Respiratory Journal</i> , 2022, 60, 2200194.	3.1	0
401	Azithromycin through the Lens of the COVID-19 Treatment. <i>Antibiotics</i> , 2022, 11, 1063.	1.5	12
402	The Lung Microbiota Affects Pulmonary Inflammation and Oxidative Stress Induced by PM _{2.5} Exposure. <i>Environmental Science & Technology</i> , 2022, 56, 12368-12379.	4.6	24
403	Targeting treatable traits allows a personalised approach to management of (severe) asthma. , 0, , .		0
404	Respiratory Reviews in Asthma 2022. <i>Tuberculosis and Respiratory Diseases</i> , 2022, 85, 283-288.	0.7	1
405	Non-typeable <i>Haemophilus influenzae</i> airways infection: the next treatable trait in asthma?. <i>European Respiratory Review</i> , 2022, 31, 220008.	3.0	6

#	ARTICLE	IF	CITATIONS
406	Burden and unmet needs in asthma care in the Asiaâ€Pacific region. , 2022, 1, 1-12.		0
407	Viral Infection and Airway Epithelial Immunity in Asthma. International Journal of Molecular Sciences, 2022, 23, 9914.	1.8	11
409	Overview of recent advancements in asthma management. Internal Medicine Journal, 2022, 52, 1478-1487.	0.5	0
410	Recent insights in the role of biomarkers in severe asthma management. Frontiers in Medicine, 0, 9, .	1.2	7
411	Clinical implications of asthma endotypes and phenotypes. Allergy and Asthma Proceedings, 2022, 43, 375-382.	1.0	5
412	Home Administration of Biologics for Severe Asthmaâ€”A Good Option for Some but Not All. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2324-2325.	2.0	0
413	Narrative Review of the Mechanisms and Treatment of Cough in Asthma, Cough Variant Asthma, and Non-asthmatic Eosinophilic Bronchitis. Lung, 2022, 200, 707-716.	1.4	9
414	Advances in Evaluation and Treatment of Severe Asthma (Part Two). Medical Clinics of North America, 2022, 106, 987-999.	1.1	0
415	Asthma and COPD: distinct diseases or components of a continuum?. , 2023, , 195-216.		0
416	Eosinophilic and noneosinophilic asthma: Beyond severe asthma. , 2023, , 31-46.		0
417	Macrophage migration inhibitory factor promotes glucocorticoid resistance of neutrophilic inflammation in a murine model of severe asthma. Thorax, 2023, 78, 661-673.	2.7	8
418	Indian Guidelines for Diagnosis of Respiratory Allergy. The Indian Journal of Chest Diseases & Allied Sciences, 2022, 63, 223-348.	0.1	0
419	PENGALAMAN PERAWAT YANG PERNAH TERKONFIRMASI COVID-19 DI RSUD SULTAN SURIANSYAH. , 2021, 2, 127-142.		0
420	Airway Epithelial Cell Junctions as Targets for Pathogens and Antimicrobial Therapy. Pharmaceutics, 2022, 14, 2619.	2.0	8
421	Analysis of drug therapy for bronchial asthma. Bulletin Physiology and Pathology of Respiration, 2022, 1, 138-148.	0.0	0
422	Treating asthma in the time of COVID. Journal of Allergy and Clinical Immunology, 2023, 151, 809-817.	1.5	1
423	Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma. Open Respiratory Archives, 2023, 5, 100231.	0.0	3
425	Respiratory comorbidities in severe asthma: focus on the pediatric age. Expert Review of Respiratory Medicine, 0, , 1-13.	1.0	2

#	ARTICLE	IF	CITATIONS
426	Indian Guidelines for diagnosis of respiratory allergy. Indian Journal of Allergy Asthma and Immunology, 2023, 37, 1.	0.1	0
427	Asthma in Childhood: Current Perspectives on Diagnosis and Treatment. European Medical Journal Respiratory, 0, , 90-99.	1.0	0
429	Effect of Azithromycin on Exacerbations in Asthma Patients with Obesity: Protocol for a Multi-Center, Prospective, Single-Arm Intervention Study. International Journal of Environmental Research and Public Health, 2023, 20, 1861.	1.2	1
431	“The effect of 48-weeks azithromycin therapy on levels of soluble biomarkers associated with HIV-associated chronic lung disease” International Immunopharmacology, 2023, 116, 109756.	1.7	2
433	Sex-Based Differences in Bronchial Asthma: What Are the Mechanisms behind Them?. Applied Sciences (Switzerland), 2023, 13, 2694.	1.3	3
434	Emerging role for interferons in respiratory viral infections and childhood asthma. Frontiers in Immunology, 0, 14, .	2.2	3
435	MAIT cells and the microbiome. Frontiers in Immunology, 0, 14, .	2.2	5
436	Asthma Exacerbations in Severe Asthma: Why Systemic Corticosteroids May not Always Be the Best Treatment Option. Current Treatment Options in Allergy, 2023, 10, 53-63.	0.9	1
437	Progress in Pathogenesis and Treatment of Cough Asthma. Advances in Clinical Medicine, 2023, 13, 2911-2917.	0.0	0
438	Executive summary: Japanese guidelines for adult asthma (JGL) 2021. Allergology International, 2023, 72, 207-226.	1.4	10
439	Prospects for macrolide therapy of asthma and COPD. Advances in Pharmacology, 2023, , 83-110.	1.2	3
441	Long-term effects of a tailored mindfulness-based program for Chinese intensive care unit nurses: A randomized parallel-group trial. Nurse Education in Practice, 2023, 70, 103640.	1.0	0
442	Cytokine-targeted therapies for asthma and COPD. European Respiratory Review, 2023, 32, 220193.	3.0	7
443	T2-Low Asthma: A Discussed but Still Orphan Disease. Biomedicines, 2023, 11, 1226.	1.4	2
444	The role of precision medicine in bronchiectasis: emerging data and clinical implications. Expert Review of Respiratory Medicine, 2023, 17, 279-293.	1.0	0
459	Heterogeneity of Treatment Response to Asthma. Advances in Experimental Medicine and Biology, 2023, , 143-161.	0.8	1
464	Exploring the influence of the microbiome on the pharmacology of anti-asthmatic drugs. Naunyn-Schmiedeberg's Archives of Pharmacology, 0, , .	1.4	0
467	Asthma and COPD: A Focus on β^2 -Agonists “ Past, Present and Future. Handbook of Experimental Pharmacology, 2023, , .	0.9	0

#	ARTICLE	IF	CITATIONS
476	Macrolides in Acute Respiratory Distress Syndrome and Acute Lung Injury. , 2024, , 177-194.		0
477	Macrolides and Inflammatory Cells, Signaling, and Mediators. , 2024, , 25-41.		0
478	Macrolide Use in Preschool-Aged Children with Acute or Recurrent Respiratory Tract Illnesses with Wheezing. , 2024, , 271-281.		0
480	Macrolides and Diseases Associated with Loss of Epithelial Barrier Integrity. , 2024, , 3-23.		0
481	Macrolides and Asthma Therapy. , 2024, , 149-160.		0
489	Natural Products for the Management of Asthma and COPD. Handbook of Experimental Pharmacology, 2024, , .	0.9	0